Abstract
Objective: Cyclophosphamide (CPA) is a chemotherapeutic agent, induces hepatotoxicity as one of its side effects. Therefore, the present work was designed to investigate the protective role of bone marrow-derived mesenchymal stem cells (BM-MSCs) on CPA–induced hepatotoxicity in Ehrlich Ascites Carcinoma bearing-mice (EAC) and to test whether BM-MSCs influences the antitumor properties of the CPA.
 Methods: The hepatoprotective effects of BM-MSCs (single dose of 100 µl of a cell suspension containing allogenic BM-MSCs, i. v.) was evaluated in a model of hepatotoxicity by CPA (10 mg/kg/d i. p.) in EAC-female mice for one month. The anti-tumor activities of CPA and BM-MSCs were assessed by measuring mean tumor weight, mean survival time and the increase in life span. Moreover, ALT, AST, GGT, MDA, GSH, SOD, IL-6, IL10, caspase-3 and Bcl2 were measured.
 Results: The i. p. administration of CPA and BM-MSCs resulted in significant reductions in tumor size and mean tumor weight as well as caused concurrent significant increases in the life span as compared to the EAC mice. Furthermore, BM-MSCs ameliorated the liver enzyme markers namely ALT, AST, GGT, and hepatic oxidative stress through inhibition of MDA level that correlated with significant improvement in antioxidant status via increasing GSH and SOD levels as compared to both EAC and EAC+CPA groups. Moreover, BM-MSCs treatment significantly reduced the inflammatory marker level IL-6 as well as increment the level of IL-10 with subsequent decreases apoptosis via a depletion in the caspase-3 associated with an enhancement in the level of Bcl2 as compared to EAC group and EAC+CPA group. Minor histological lesions were observed in the liver tissue sections of mice treated with CPA and BM-MSCs as compared to the high histological lesions observed in the liver of the EAC group and CPA treated group.
 Conclusion: These results concluded that the combination treatment of BM-MSCs with CPA exhibited promising potential antitumor efficacy with greater safety than CPA treatment alone in mice via its antioxidant, anti-inflammatory and antiapoptotic effects.
Highlights
Cancer is one of the greatest serious diseases everywhere throughout the world
The result of this study showed that hepatic IL-6 level displayed significant elevation (P
The current study showed that CPA, bone marrow-derived mesenchymal stem cells (BM-Mesenchymal stem cells (MSCs)) or CPA and BM-MSCs administration significantly reduced the solid tumor burden in mice and enhanced the survival time of EAC bearing mice, especially in the co-administration of CPA and BM-MSCs which caused an increase in the life span of animals and the tumor inhibition ratio [28]
Summary
Cancer therapy and its managing depend fundamentally on the utilization of chemotherapeutic agents. These agents mainly target the rapidly proliferating neoplastic cells in cancer patients. Cyclophosphamide (CPA) is used as a chemotherapeutic drug [3]. Preceding studies have exhibited that CPA could produce substantial reactive oxygen species (ROS) and add to succeeding raised concentrations of highly cytotoxic oxidative stress-resulting lipid peroxidation aldehydes, such as acrolein and malondialdehyde (MDA) [5]. Hepatotoxicity has been recorded in patients injected intravenously with a low dose of CPA [7]. Preceding studies have indicated that liver toxicity is a significant issue related to cyclophosphamide application [8]
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have